Merck xuelanuo soft tissue sarcoma drug th-302 approved for domestic clinical use
-
Last Update: 2015-02-10
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Merck xuelanuo's soft tissue sarcoma drug th-302 was approved for clinical use in China on February 5, 2015, and its current status is "under approval" Th-302, developed by threshold and Merck, is used in anoxic solid tumors Hypoxia is the characteristic of most hematological malignancies The clinical history of th-302 has gone through ups and downs A few years ago, the drug did not reach a very important end-point of overall survival At the same time, in 2014, threshold company told investors that it had to pass the mid-term analysis and final analysis of the soft tissue sarcoma phase 3 study Fortunately, as one of the most concerned products in Merck's key late trial drugs, th-302 was qualified for FDA fast track review at the end of 2014, which also brought a 10% share price surge to threshold.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
